Three AstraZeneca patents ruled invalid in Australia

Drugs giant AstraZeneca has reported that the Federal Court of Australia has found three patents protecting the company's Crestor treatment to be invalid, after they were challenged by several pharmaceutical firms.

Drugs giant AstraZeneca has reported that the Federal Court of Australia has found three patents protecting the company's Crestor treatment to be invalid, after they were challenged by several pharmaceutical firms.

The court's decision only affects the patent in Australia and does not have an impact on the validity of patents related to Crestor in any other country.

Total sales of Crestor in Australia for 2012 were approximately $350m.

In a statement the group said: "AstraZeneca is disappointed in the court's decision to find these patents invalid. The company remains committed to defending its intellectual property protecting Crestor in Australia and is carefully reviewing this decision and evaluating all legal options at this time, which could include filing an appeal and seeking to maintain existing preliminary injunctions."

Of the patents, one was a formulation patent, the second was related to the use of rosuvastatin for treating heterozygous familial hypercholesterolemia (high cholesterol), and the third was related to the use of rosuvastatin for treating hypercholesterolemia.

The share price was up 0.47% to 3,022p by 09:05.

NR

Recommended

Three strong Asian stocks trading at bargain prices
Share tips

Three strong Asian stocks trading at bargain prices

Professional investor Nitin Bajaj of the Fidelity Asian Values investment trust picks three stocks that dominate their industries, earn good returns o…
20 Sep 2021
Why it pays to face up to your investment mistakes
Investment strategy

Why it pays to face up to your investment mistakes

Buying stocks can be a complicated business. But selling stocks can be tricky, too – even if you sell for the right reasons. Max King explains how to …
17 Sep 2021
Share tips of the week – 17 September
Share tips

Share tips of the week – 17 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Sep 2021
Royal Mail will deliver for investors – here's how to play it
Trading

Royal Mail will deliver for investors – here's how to play it

Royal Mail Group has found its feet in the past 18 months and looks cheap. Matthew Partridge looks at how to trade the shares.
14 Sep 2021

Most Popular

The times may be changing, but don’t change how you invest
Small cap stocks

The times may be changing, but don’t change how you invest

We are living in strange times. But the basics of investing remain the same: buy fairly-priced stocks that can provide an income. And there are few be…
13 Sep 2021
Two shipping funds to buy for steady income
Investment trusts

Two shipping funds to buy for steady income

Returns from owning ships are volatile, but these two investment trusts are trying to make the sector less risky.
7 Sep 2021
How to stop recurring subscriptions becoming a drain on your money
Personal finance

How to stop recurring subscriptions becoming a drain on your money

Tracking and pruning subscriptions isn’t as easy as it sounds. Here's how to take charge.
14 Sep 2021